A Phase 1 interventional study of TQ05105 tablets and Itraconazole capsule in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.
Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 2nd registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–75 · Healthy volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 3
First in 2021; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 28 across the 10 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
3 of the studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07708272Chia Tai Tianqing Pharmaceutical Group Co., Ltd.QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants | 2026-12 |
| NCT07608666Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets | 2026-12 |
| NCT06122831Chia Tai Tianqing Pharmaceutical Group Co., Ltd.A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Itraconazole capsule: 0.2g once daily on Days 2 to Day 5; TQ05105 tablets: single oral dose on Days 1 and Day 5.
Drug: TQ05105 tablets · Drug: Itraconazole capsule
Rifampicin Capsule: 0.6g once daily on Days 2 to Day 9; TQ05105 tablets: single oral dose on Days 1 and Day 9.
Drug: TQ05105 tablets · Drug: Rifampicin Capsule
TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
Rifampicin is a strong inducer of CYP3A.
Maximum plasma concentration (Cmax)
Maximum plasma drug concentration after administration.
Time frame: Up to 10 days.
Time to reach Cmax (Tmax)
Time to reach the maximum plasma concentration after administration.
Time frame: Up to 10 days.
Elimination half-life (t1/2)
The elimination half-life (t1/2) after oral dose of TQ05105 tablets and Itraconazole capsule.
Time frame: Up to 6 days.
Occurrence of adverse events (AE)
Including all adverse events (AE) and serious adverse events (SAE).
Time frame: Up to 30 days.
Ran from Sep 2023 to primary completion in Jan 2024, 4 months.
Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JAK2 Inhibitor TQ05105
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →